CG Invites Co., Ltd. (KOSDAQ:083790)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,045.00
+5.00 (0.25%)
May 30, 2025, 3:30 PM KST
-17.87%
Market Cap 157.25B
Revenue (ttm) 9.62B
Net Income (ttm) -48.80B
Shares Out 76.89M
EPS (ttm) -634.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 139,447
Average Volume 145,543
Open 2,040.00
Previous Close 2,040.00
Day's Range 2,000.00 - 2,060.00
52-Week Range 1,900.00 - 3,145.00
Beta 0.56
RSI 46.53
Earnings Date May 13, 2025

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 83
Stock Exchange KOSDAQ
Ticker Symbol 083790
Full Company Profile

Financial Performance

In 2024, CG Invites's revenue was 7.25 billion, an increase of 48.67% compared to the previous year's 4.88 billion. Losses were -51.54 billion, 5.36% more than in 2023.

Financial Statements

News

There is no news available yet.